Jiangsu Nhwa Pharmaceutical Co Ltd - Asset Resilience Ratio
Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has an Asset Resilience Ratio of 26.45% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002262 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Jiangsu Nhwa Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 002262 asset base.
Liquid Assets Composition Over Time
This chart breaks down Jiangsu Nhwa Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Jiangsu Nhwa Pharmaceutical Co Ltd (002262) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.52 Billion | 26.45% |
| Total Liquid Assets | CN¥2.52 Billion | 26.45% |
Asset Resilience Insights
- Very High Liquidity: Jiangsu Nhwa Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 26.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jiangsu Nhwa Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jiangsu Nhwa Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Jiangsu Nhwa Pharmaceutical Co Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Jiangsu Nhwa Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.85% | CN¥2.57 Billion ≈ $375.93 Million |
CN¥9.22 Billion ≈ $1.35 Billion |
-0.26pp |
| 2024-12-31 | 28.12% | CN¥2.37 Billion ≈ $347.24 Million |
CN¥8.44 Billion ≈ $1.24 Billion |
+9.90pp |
| 2023-12-31 | 18.22% | CN¥1.33 Billion ≈ $195.35 Million |
CN¥7.33 Billion ≈ $1.07 Billion |
-4.19pp |
| 2022-12-31 | 22.40% | CN¥1.45 Billion ≈ $212.47 Million |
CN¥6.48 Billion ≈ $948.40 Million |
+3.83pp |
| 2021-12-31 | 18.58% | CN¥1.06 Billion ≈ $154.88 Million |
CN¥5.70 Billion ≈ $833.68 Million |
+1.18pp |
| 2020-12-31 | 17.39% | CN¥837.00 Million ≈ $122.48 Million |
CN¥4.81 Billion ≈ $704.17 Million |
+15.73pp |
| 2019-12-31 | 1.67% | CN¥70.00 Million ≈ $10.24 Million |
CN¥4.20 Billion ≈ $614.81 Million |
-1.68pp |
| 2018-12-31 | 3.35% | CN¥135.00 Million ≈ $19.75 Million |
CN¥4.03 Billion ≈ $590.13 Million |
-6.83pp |
| 2017-12-31 | 10.18% | CN¥336.05 Million ≈ $49.17 Million |
CN¥3.30 Billion ≈ $483.12 Million |
+6.14pp |
| 2016-12-31 | 4.03% | CN¥120.00 Million ≈ $17.56 Million |
CN¥2.97 Billion ≈ $435.32 Million |
-- |
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin… Read more